As health authorities work to contain the ongoing Bundibugyo Ebola outbreak in Central Africa, the World Health Organization has identified several promising therapeutic and vaccine candidates for urgent clinical evaluation. The recommendations come amid continued transmission in the Democratic Republic of the Congo and reported cases in Uganda. With no approved therapies or vaccines specifically targeting the Bundibugyo strain, WHO and an international panel of experts have moved quickly to establish priorities for clinical research and evidence generation.
Among therapeutic candidates, the agency highlighted MBP134, an experimental monoclonal antibody developed by Mapp Biopharmaceutical, Regeneron's maftivimab, and the antiviral remdesivir. WHO experts also recommended exploring combination approaches that pair a monoclonal antibody with remdesivir, reflecting growing interest in…
